Non Small Cell Lung Cancer Clinical Trials in Ann Arbor, Michigan

9 studies are recruiting for non small cell lung cancer in Ann Arbor, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

   Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clinical Study Site, Ann Arbor, Michigan

   Locations

   285 in total

   Run by

   Summit Therapeutics

   See if you can join NCT06767514 on ClinicalTrials.gov

2. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

   This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Michigan, Ann Arbor, Michigan

   Locations

   38 in total

   Run by

   Genentech, Inc.

   See if you can join NCT04302025 on ClinicalTrials.gov

3. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

   This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival ass…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Michigan, Ann Arbor, Michigan

   Locations

   260 in total

   Run by

   Summit Therapeutics

   See if you can join NCT05899608 on ClinicalTrials.gov

4. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

   The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that int…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Michigan Clinical Trials Office ( Site 0058), Ann Arbor, Michigan

   Locations

   229 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06077760 on ClinicalTrials.gov

5. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

   This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Michigan, Ann Arbor, Michigan

   Locations

   14 in total

   Run by

   Verastem, Inc.

   See if you can join NCT07020221 on ClinicalTrials.gov

6. Repositioning Immunotherapy in VetArans With Lung Cancer

   This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan

   Locations

   7 in total

   Run by

   VA Office of Research and Development

   See if you can join NCT06275360 on ClinicalTrials.gov

7. A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

   The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Michigan (Data Collection Only), Ann Arbor, Michigan

   Locations

   10 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07428044 on ClinicalTrials.gov

8. EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

   This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will be enrolled at multi…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan

   Locations

   5 in total

   Run by

   VA Office of Research and Development

   See if you can join NCT05467748 on ClinicalTrials.gov

9. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Ann Arbor, Michigan

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov